| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma.InnFocus is an ophthalmology company founded in 2003 with extensive biomaterials experience that develops and provides next generation products for glaucoma surgery. Glaucoma is a disease for which there is no cure, is the second leading cause of blindness in the world and afflicts an estimated 60 million people worldwide.
Waiting Room Solutions is a Goshen, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Century Healthcare provides functional solutions to help employers meet the challenges of today`s complex healthcare environment. We are an organization committed to the design, implementation and administration of customized benefit plans for employers of all sizes throughout the U.S.
ValiMation, Inc. is a Paoli, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.